FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3178909880> ?p ?o ?g. }

• W3178909880 endingPage "CT177" @default.
• W3178909880 startingPage "CT177" @default.
• W3178909880 abstract "Abstract Background: Improving outcomes of PDAC with checkpoint inhibitors (CPIs) have been ineffective, underscoring the need to co-target alternative pathways. Preclinical data showed that CXCR4-SDF1 axis modulates the tumor microenvironment (TME) in PDAC and that CXCR4 inhibition enhances T cell access to the TME, increasing tumor sensitivity to CPIs. This was confirmed in the COMBAT Cohort 1 (CC1) study showing that the dual combination M+P increases activated CD8+ T cells and decreases myeloid derived suppressor cells (MDSCs) within the TME. Moreover, our pre-clinical studies showed that adding C to M+P resulted in improved efficacy vs C alone. The COMBAT Cohort 2 (CC2) aims to test the safety and efficacy of the triple combination of M+P+C in 2L mPDAC. Methods: Single arm phase 2a study in mPDAC. In cohort 2, patients with stage IV PDAC at diagnose who had progressed to 1L gemcitabine-based C received 5 days M priming, followed by M BIW + P Q3W plus C [Irinotecan liposomal injection/5-FU/LV (OFL)] Q2W. The primary endpoint was RR. Results: A total of 43 patients with stage 4 PDAC, 98% of whom were diagnosed with stage 4 disease, were enrolled. Median age was 68 (40-85) and 74.4% had liver disease. The safety profile was consistent with the individual profiles of each treatment alone. Of note, the incidence of ≥G3 neutropenia (G3Neu) was 7% and ≥G3 infection was 7%, which is lower than expected for C (OFL) alone (20% and 17%, respectively). The levels of T-cells increased during M priming and returned to normal values, which remained stable across the study despite the OFL treatment. For the evaluable patients (N=38) the ORR was 21.1% with a 13.2% confirmed ORR (defined as two consecutive assessments showing PR) and a 63.2% DCR (PR+SD). Median duration of clinical benefit was 5.6 months. Median OS and PFS were 6.5 months and 4.0 months, respectively (6.6 months and 3.8 months, respectively, for the ITT population). Conclusions: The triple combination of M+P+C is tolerable and shows encouraging results with cORR 13.2%, mPFS 4.0 months and mOS 6.5 months (compared to 7.7%, ~3 months and 4.7 months, respectively, on a historical basis for OFL alone in the stage 4 diagnosis subpopulation). SD of 42.1% and DCR of 63.2% were also higher than historical data on SoC chemotherapy used in 2L patients. The incidence of severe neutropenia and infections is lower than the historical data on C. The results from the CC2 suggest that M+P may expand the efficacy and safety benefit of OFL in PDAC, and warrants further investigation in a randomized study. Citation Format: Manuel Hidalgo, Teresa Macarulla, Valerya Semenisty, Erkut Borazanci, Jaime Feliu, Mariano Ponz-Sarvise, David Gutierrez Abad, Paul Oberstein, Angela Alistar, Andres Muñoz, Ravit Geva, Carmen Guillén-Ponce, Mercedes Salgado Fernandez, Amnon Peled, Marya Chaney, Irit Glicko-Kabir, Liron Shemesh-Darvish, Debby Ickowicz, Ella Sorani, Shaul E. Kadosh, Abi Vainstein-Haras, Bruno Bockorny. A multi-center phase 2a trial of the CXCR4 inhibitor motixafortide (BL-8040) (M) in combination with pembrolizumab (P) and chemotherapy (C), in patients with metastatic pancreatic adenocarcinoma (mPDAC) [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr CT177." @default.
• W3178909880 created "2021-07-19" @default.
• W3178909880 creator A5000204001 @default.
• W3178909880 creator A5006976704 @default.
• W3178909880 creator A5008124413 @default.
• W3178909880 creator A5011188091 @default.
• W3178909880 creator A5015984085 @default.
• W3178909880 creator A5016208717 @default.
• W3178909880 creator A5023523894 @default.
• W3178909880 creator A5025524401 @default.
• W3178909880 creator A5034725846 @default.
• W3178909880 creator A5047689477 @default.
• W3178909880 creator A5050481393 @default.
• W3178909880 creator A5050960262 @default.
• W3178909880 creator A5052465396 @default.
• W3178909880 creator A5054053039 @default.
• W3178909880 creator A5060798513 @default.
• W3178909880 creator A5065263314 @default.
• W3178909880 creator A5067132848 @default.
• W3178909880 creator A5068892140 @default.
• W3178909880 creator A5070523850 @default.
• W3178909880 creator A5072991940 @default.
• W3178909880 creator A5073278280 @default.
• W3178909880 creator A5086660695 @default.
• W3178909880 date "2021-07-01" @default.
• W3178909880 modified "2023-10-03" @default.
• W3178909880 title "Abstract CT177: A multi-center phase 2a trial of the CXCR4 inhibitor motixafortide (BL-8040) (M) in combination with pembrolizumab (P) and chemotherapy (C), in patients with metastatic pancreatic adenocarcinoma (mPDAC)" @default.
• W3178909880 doi "https://doi.org/10.1158/1538-7445.am2021-ct177" @default.
• W3178909880 hasPublicationYear "2021" @default.
• W3178909880 type Work @default.
• W3178909880 sameAs 3178909880 @default.
• W3178909880 citedByCount "2" @default.
• W3178909880 countsByYear W31789098802022 @default.
• W3178909880 countsByYear W31789098802023 @default.
• W3178909880 crossrefType "journal-article" @default.
• W3178909880 hasAuthorship W3178909880A5000204001 @default.
• W3178909880 hasAuthorship W3178909880A5006976704 @default.
• W3178909880 hasAuthorship W3178909880A5008124413 @default.
• W3178909880 hasAuthorship W3178909880A5011188091 @default.
• W3178909880 hasAuthorship W3178909880A5015984085 @default.
• W3178909880 hasAuthorship W3178909880A5016208717 @default.
• W3178909880 hasAuthorship W3178909880A5023523894 @default.
• W3178909880 hasAuthorship W3178909880A5025524401 @default.
• W3178909880 hasAuthorship W3178909880A5034725846 @default.
• W3178909880 hasAuthorship W3178909880A5047689477 @default.
• W3178909880 hasAuthorship W3178909880A5050481393 @default.
• W3178909880 hasAuthorship W3178909880A5050960262 @default.
• W3178909880 hasAuthorship W3178909880A5052465396 @default.
• W3178909880 hasAuthorship W3178909880A5054053039 @default.
• W3178909880 hasAuthorship W3178909880A5060798513 @default.
• W3178909880 hasAuthorship W3178909880A5065263314 @default.
• W3178909880 hasAuthorship W3178909880A5067132848 @default.
• W3178909880 hasAuthorship W3178909880A5068892140 @default.
• W3178909880 hasAuthorship W3178909880A5070523850 @default.
• W3178909880 hasAuthorship W3178909880A5072991940 @default.
• W3178909880 hasAuthorship W3178909880A5073278280 @default.
• W3178909880 hasAuthorship W3178909880A5086660695 @default.
• W3178909880 hasConcept C121608353 @default.
• W3178909880 hasConcept C126322002 @default.
• W3178909880 hasConcept C143998085 @default.
• W3178909880 hasConcept C203092338 @default.
• W3178909880 hasConcept C2776107976 @default.
• W3178909880 hasConcept C2776694085 @default.
• W3178909880 hasConcept C2777063308 @default.
• W3178909880 hasConcept C2777701055 @default.
• W3178909880 hasConcept C2780057760 @default.
• W3178909880 hasConcept C2780258809 @default.
• W3178909880 hasConcept C535046627 @default.
• W3178909880 hasConcept C71924100 @default.
• W3178909880 hasConcept C72563966 @default.
• W3178909880 hasConcept C90924648 @default.
• W3178909880 hasConceptScore W3178909880C121608353 @default.
• W3178909880 hasConceptScore W3178909880C126322002 @default.
• W3178909880 hasConceptScore W3178909880C143998085 @default.
• W3178909880 hasConceptScore W3178909880C203092338 @default.
• W3178909880 hasConceptScore W3178909880C2776107976 @default.
• W3178909880 hasConceptScore W3178909880C2776694085 @default.
• W3178909880 hasConceptScore W3178909880C2777063308 @default.
• W3178909880 hasConceptScore W3178909880C2777701055 @default.
• W3178909880 hasConceptScore W3178909880C2780057760 @default.
• W3178909880 hasConceptScore W3178909880C2780258809 @default.
• W3178909880 hasConceptScore W3178909880C535046627 @default.
• W3178909880 hasConceptScore W3178909880C71924100 @default.
• W3178909880 hasConceptScore W3178909880C72563966 @default.
• W3178909880 hasConceptScore W3178909880C90924648 @default.
• W3178909880 hasIssue "13_Supplement" @default.
• W3178909880 hasLocation W31789098801 @default.
• W3178909880 hasOpenAccess W3178909880 @default.
• W3178909880 hasPrimaryLocation W31789098801 @default.
• W3178909880 hasRelatedWork W1936678075 @default.
• W3178909880 hasRelatedWork W2080820783 @default.
• W3178909880 hasRelatedWork W2113566724 @default.
• W3178909880 hasRelatedWork W2315587357 @default.
• W3178909880 hasRelatedWork W2796582438 @default.
• W3178909880 hasRelatedWork W2892640821 @default.
• W3178909880 hasRelatedWork W2900258459 @default.
• W3178909880 hasRelatedWork W4210363402 @default.
• W3178909880 hasRelatedWork W4281711210 @default.

• next